Abdelilah Aboussekhra is currently Principal Scientist at the King Faisal Specialist Hospital and Research Center, Riyadh. He is head of the Cancer Biology and Experimental Therapeutics Section and Chairman of the Molecular Oncology Department at the Research Center. He obtained his Ph.D. degree in Jun 1992 from Orsay University (Paris XI). From 1992 to 1995 he worked as Post-Doctoral fellow in the Imperial Cancer Research Found (Clare Hall, London) on the reconstitution of the nucleotide excision repair process in vitro using purified factors. In 1996 he joined the institute of cell Biology (ETH, Zurich) where he worked as associate scientist for 2 years on the role of chromatin in modulating nucleotide excision repair. He joined King Faisal Specialist Hospital and Research center as Scientist and head of the DNA repair and Apoptosis section in 1998. His major research interest has been the role of the tumor suppressor p16 protein and tumor microenvironment in breast cancer development and therapy. He published more than 60 papers and reviews and received several research achievement awards.
Deputy Executive Director of the Research Centre at King Faisal Specialist Hospital and Research Centre (KRSHRC) in Saudi Arabia. Director of BioMolecular Research Program and Principal Senior Scientist in the field of molecular biology and immunology. Holds an appointment as Adjunct Staff at the Department of Cancer Biology, Lerner Research Institute in Cleveland Clinic Foundation. Received Ph.D from University of Pittsburgh, 1993. Recipient of the U.S. National Delta Omega Honor, International Cancer Technology Transfer Award from the International Union Against Cancer (UICC) in 2000. Recipient of the first Outstanding Scientist Award in KFSHRC 2002 and several Research Achievement Awards from KFSH&RC. Recipient of the Crown Prince-sponsored Tomorrow Award, 2010 and the King’s award for inventors and talents (2012). Published over 72 peer-reviewed full-length papers with high citation index of 51 per paper, including five invited reviews on RNA regulation of cytokines. Principal Investigator on competitive local institutional grants. Co-investigator or Collaborator on a number of international grants including NIH sub-contract. Active reviewer/guest editor/Associate Editor for several U.S. and international journals in the cytokine regulation and RNA stability field. Grant reviewer for a number of international funding agencies including U.S. National Science Foundation and U.K. Medical Research Council. Invited for lectures in academic institutions and conference plenary sessions. Member or board member of several national biotechnology development committees. Has more than 12 issued patents in molecular biology the field of molecular biology and biotechnology. Expert in molecular cytokine biology, innate immunity, and post-transcriptional control of gene expression.
Dr. Huda Al-Khalaf is currently Associate Professor at King Abdulaziz City for Science and Technology, The National Centre for Stem Cell Technology, Riyadh, Scientist at the Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, and Associate Professor at the school of Medicine, Al-Faisal University, Riyadh.
Dr. Al-Khalaf obtained her Ph.D. degree in Molecular Oncology from Cardiff University, UK in 2010. After then she developed new innovative projects and collaborations with national and international research groups on the role of the tumor suppressor p16 in carcinogenesis including response to DNA damage, EMT and aging.
She has published more than 20 papers in peer-reviewed journals and delivered more than 50 invited lectures at national, regional and international platforms.
Dr. Al-Khalaf is the PI of several funded research grant projects. She has received numerous research achievement awards, including the 2016 Prince Saud Bin Nayef Award for Excellence in Cancer Research.
Dr. Al-Khalaf is a regular reviewer for several internationally reputed Journals and very much involved in many national and international education activities related to Cancer Research.
She is a member of Women Empowerment Program at KACST and an active member of multiple Professional organizations including American Association of Cancer Research and the American Society for Microbiology.
Currently, her main interest is directed towards dissecting the molecular role of obesity in the development and spread of Breast Cancer, and she is keen to generate new information and testing the real value of the technology in clinical practice.
Dr. Ghebeh is a scientist interested in the immunomodulation, and resistance to therapy of a subpopulation of breast cancer cell called breast cancer stem cells (CSC). He focuses on understanding the interaction of CSCs with the immune system for their targeting and eradication. Dr. Ghebeh et al he previously characterized the expression and the mechanism of PD-L1 expression in breast cancer and later one studied the hierarchy of epithelial stem/progenitor cell populations in normal and malignant breast. Dr. Ghebeh has a degree in pharmacy and completed his Ph.D. from University of Manitoba, Winnipeg, Canada and got a postdoctoral training in Sanofi-Aventis, Toronto, Canada. He is an author of over 22 peer-reviewed original research and review articles and PI of several funded grants. In addition to his full time scientist job in KFSH&RC, Riyadh, Saudi Arabia, Dr. Ghebeh holds an assistant professor position from college of medicine, Al-Faisal University Riyadh, Saudi Arabia.
Dr. Monther AlAlwan is a scientist at the Stem Cell and Tissue Re-engineering Program (SCTRP), King Faisal Specialist Hospital and Research Centre, as well as an Associate professor at Alfaisal University, Riyadh Saudi Arabia. He holds M.Sc. and Ph.D. in Immunology from Dalhousie University (Halifax, Canada). Dr. AlAlwan conducted a 3-years postdoctoral fellowship studying signaling in immune cells at the University of Manitoba, Canada. During his graduate studies and postdoctoral fellowship, Dr. AlAlwan made substantial contribution in the immunology field, particularly his groundbreaking discovery that highlighted the significance of the dendritic cells in the immunological synapse. After joining the SCTRP in 2007, he shifted gear to study cancer, where he identified novel mechanisms that regulate cancer metastasis and chemoresistance. Currently, he is actively involved in dissecting the molecular pathways that regulate the function of cancer stem cells and how this related to chemoresistance and metastasis. Dr. AlAlwan is an author in 25 peer-reviewed publications, has delivered several invited lectures and is a regular reviewer for various international journals.
Dr. Ali H. Alhasan is a nanoscientist with research interests in nanomedicine. He is an Assistant Research Professor at King Abdualziz City for Science and Technology (KACST), the co-director of the KACST-BWH/Harvard center of excellence for biomedicine a principal investigator of the nanomedicine research group, and an adjunct assistant professor at Alfaisal University. He completed his PhD studies in the laboratory of Professor Chad Mirkin at Northwestern University. Then, he joined the Center of Excellence in Nanomedicine (CENM) as the director of strategic initiatives, and the laboratory of Professor Adah Almutairi at University of California-San Diego as a postdoctoral researcher.
His research focuses on the biochemical properties of nanoconjugates and the interaction of such structures with biological moieties in a cellular environment in order to develop rationally designed non-viral drug delivery nano-platforms. He has published papers on his advances in biological diagnostics, gene therapy, and nano-drug delivery in high impact journals like PNAS, ACS Nano, JACS, Small, Scientific Reports, and Analytical Chemistry.
He is a co-inventor of the Nano-metric microRNA profiler (Scano-miR) and co-developed the Nano-Lipo product. He has been the recipient of recognitions including the International Institute for Nanotechnology Outstanding Researcher, a Kemin outstanding researcher, and a King Abdullah Scholarship.
Dr. Abdulaziz Almalik’s is the executive director for the Life Science and Environment Research Institute (LSERI) at KACST. He is an Associate Professor of Pharmaceutical Sciences. He is a founding member of the center of excellence for Biomedicine, chairing its governing board, in addition to his role as a principal investigator. He received his PhD in Pharmaceutical Sciences from the University of Manchester, United Kingdom in 2013 with Professor Nicola Tirelli. Dr. Almalik’s research interest is the molecular design of nanomaterials and their interactions with biological environments in responsive fashion. In particular, Almalik research focuses on the interactions of cells with nanomaterials as well as the effect of such interactions on the delivery of macromolecular payloads. His research activities also cover the study of the bionano interface and the general utilization of nanomaterials in biomedical (delivery, sensing and imaging) applications. To date, he published fifteen research articles on the advancements of nanomedicine in prestigious journals such as Biomaterials, Journal for Control Release, Scientific Reports, ACS Appl Mater Interfaces, and PLoS One.